Global AMD Drugs Market is segmented By Product Type (Wet AMD, Dry AMD), By Drug Type (Lucentis, Eylea, Avastin, Others), By Route of Administration (Intravenous, Intravitreal), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
AMD Drugs Market Size
AMD Drugs Market was valued at US$ 9,717.64 million in 2021 and is estimated to reach US$ 15,903.86 million by 2031, growing at a CAGR of 7.26% during the forecast period (2024-2031).
Age-related macular degeneration (AMD) is a problem with the retina. It happens when a part of the retina called the macula is damaged. AMD loses central vision. Age-related macular degeneration is of two types; dry AMD and wet AMD.
AMD Drugs Market Summary
|
Metrics |
Details |
|
Market CAGR |
7.26% |
|
Segments Covered |
By Product Type, By Drug Type, By Route of Administration, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights about the Market Request Free Sample
AMD Drugs Market Dynamics
Various factors are responsible for the market's growth, such as an increase in the prevalence of age-related macular degeneration across the globe and awareness among the population regarding the disease. An increase in the prevalence of the geriatric population, as they are prone to macular degeneration, is additionally contributing to the growth of the AMD drugs market.
The increasing number of novel product launches and the rising regulatory approvals will drive market growth.
The global market for AMD drugs is primarily driven by the surge in demand for these drugs due to the increasing geriatric population; the rising number of novel product launches. An increase in age-related macular degeneration cases is also aiding the market growth. Various latest AMD drugs are being launched, and several pipelines and clinical trials or studies are taking place to contribute to the growth of the global AMD drugs market. For instance, in Aug 2022, Kodiak Sciences Inc. announced positive results from the phase 3 BEACON study of tarcocimab tedromer’s (KSI-301: tarcocimab), its new antibody biopolymer conjugate met the endpoints of non-inferior change in visual acuity at 24 weeks as compared to aflibercept in macular edema patients.
Various funding, novel technological advancements, and the number of the latest innovative product launches and regulatory approvals are increasing, leading to the high demand for AMD drugs. For instance, in Oct 2021, Genentech announced the approval of Susvimo (ranibizumab injection) used via an intravitreally ocular implant for treating people with neovascular or wet age-related macular degeneration who have responded to a minimum of two anti-vascular endothelial growth factor injection by U.S. Food and Drug Administration.
The high cost associated with AMD drugs will hamper the market’s growth.
However, major factors hindering the AMD drugs market during the forecast period are the high cost associated with the drugs and the side effects of these drugs. According to the American Academy of Ophthalmology, per treatment cost of Beovu, Lucentis and Eylea is around $1,800 to $2,000. And the cost of Avastin is approximately $50.
COVID-19 Impact Analysis
The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The AMD drugs market has experienced huge losses due to COVID, as all the research and clinical trials got affected due to the diversion of attention toward COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in May 2021, BlueRock Therapeutics, a subsidiary of Bayer AG, Fujifilm Cellular Dynamics and Opsis Therapeutic LLC announced their alliance of research and development where they will develop cell therapies for ocular diseases patients.
AMD Drugs Market Segment Analysis
The wet AMD segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
The wet AMD segment is the highest market holder in the global AMD drugs market. Wet AMD growth is attributed to the increased adoption of these drugs for age-related macular degeneration treatment. Wet AMD is the main cause of blindness that impacts around 1.1. million individuals in the United States. According to the NCBI 2021, AMD is the 3rd leading cause of blindness globally. As the geriatric population increases, ADM prevalence is expected to grow, with 288 million estimated cases by 2040.
In wet AMD, a novel blood vessel grows under the retina as it grows, which can lift the retina. This blood vessel can also leak, allowing blood to seep into the retina and damage the central vision area. Some medicines, known as vascular endothelial growth factor (VEGF) inhibitors, can slow blood vessel growth. Wet AMD causes serious vision restrictions.
The wet AMD segment dominates the market due to the rising prevalence of age-related macular degeneration. The growing number of regulatory approvals, technological advancements, product launches, pipelines and research studies drive the market’s growth. For instance, in Oct 2022, Regenxbio Inc. announced positive results at the American Academy of Ophthalmology annual meeting from the RGX-314’s AAVIATE phase II trial for wet AMD, a major reason for vision loss treatment with the help of suprachoroidal delivery. It also reports positive data from RGX-314, Phase I/IIa long-term follow-up study for wet AMD with subretinal delivery.
AMD Drugs Market Geographical Share
North America holds the largest market share of the global AMD drugs market.
North America dominates the global AMD drugs market, primarily attributed to the increasing development in healthcare facilities and an increase in investment by government and non-government organizations for the development of new age-related macular degeneration drugs. The increase in the adoption of drugs for AMD treatment leading to increasing demand for these drug products and the presence of key players in the region are contributing to the growth of the AMD drugs market.
Moreover, the growing number of product launches is responsible for the market’s growth. Other factors, such as the high spending on these drugs, stimulate the market’s growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Jan 2022, Genentech, a Roche Group member, announced the approval of Vabysmo (faricimab-svoa) for treating wet age-related macular degeneration as well as diabetic macular edema, two main causes for vision loss among the U.S. adults.
AMD Drugs Companies and Competitive Landscape
The AMD Drugs market is highly competitive with local and global companies’ presence. Bayer HealthCare LLC, F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Kubota Pharmaceutical Holdings Inc., AbbVie Inc., Kodiak Sciences, Genentech Inc., Roche Group Member, Regenxbio Inc. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in September 2021, AbbVie Inc. announced its partnership with Regenxbio Inc. to develop and commercialize RGX-314, gene therapy for wet age-related macular degeneration and other retinal diseases. It is also being examined in wet AMD patients in the trial using subretinal delivery.
Bayer Healthcare LLC:
Overview:
Bayer is a biotech and pharmaceutical multinational company. It was founded in 1863 and is headquartered in Leverkusen, Germany. Their business includes pharmaceutical, agricultural chemicals, healthcare, and biotechnology products.
Product Portfolio:
Eylea: It is an approved anti-VEGF that can extend successfully for around 16-week treatment intervals during clinical trials with the T&E dosing regimen. It provides the long-lasting anti-VEGF activity.
Key Development: In Sep 2022, Bayer announced the approval of Eylea (aflibercept) intravitreal injection in Japan by the Ministry of Health, Labour and Welfare for treating preterm infants with retinopathy.
The global AMD drugs market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.
